RxDoctor Payments Data

Jessica Livesey, PA

Medical · Syracuse, NYNPI 1841918000

Payments from drug & device makers

$7,469in general payments, 2019–2025

Across 277 payments — averaging $26.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$934
  • Johnson & Johnson$657
  • E.r. Squibb & Sons, L.L.C.$451
  • Novartis$442
  • GSK$442
  • Pfizer$411
  • plus $4K from 39 others

What the payments were for

  • Food & beverage$6,71990%
  • Education$75010%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,469 in reported general payments places this provider in the 90th percentile of 2,395 medical providers in New York.

See all medical providers in New York

Medicare billing

Part B allowed, 2024
$8,406
Medicare patients
52
Services billed
106

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban20$13,705
EliquisApixaban15$10,637
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$5,137
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$2,386
Omega-3 Acid Ethyl Esters16$1,475
Gabapentin42$864
Atorvastatin Calcium64$785
SynthroidLevothyroxine Sodium11$769
Rosuvastatin Calcium51$710
Albuterol Sulfate HfaAlbuterol Sulfate26$588
Omeprazole37$572
Metoprolol Succinate26$546
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen15$422
Ondansetron OdtOndansetron13$377
Losartan Potassium25$358

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$657$13,70520 claims
PfizerEliquis$411$10,63715 claims
GSKAnoro Ellipta$442$5,13711 claims
AbbVieSynthroid$383$76911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,395 medical providers in New York.

Other medical in Syracuse

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →